03.02.2022 13:35:30
|
Biogen Posts Adj. Profit In Q4; Sees FY22 Results Below Market
(RTTNews) - Biogen Inc. (BIIB) reported that its fourth quarter non-GAAP earnings per share was $3.39 compared to a loss of $1.05, prior year. On average, 28 analysts polled by Thomson Reuters expected the company to report profit per share of $3.38, for the quarter. Analysts' estimates typically exclude special items.
Net income attributable to Biogen Inc. was $368.2 million or $2.50 per share compared to $357.9 million or $2.32 per share, previous year.
Total revenue declined to $2.73 billion from $2.85 billion, prior year. Analysts on average had estimated $2.62 billion in revenue.
For 2022, Biogen expects: non-GAAP EPS to be between $14.25 and $16.00; and revenue to be between $9.7 billion and $10.0 billion. Analysts expect the company to report profit per share of $18.85 on revenue of $10.34 billion. The company noted that its financial guidance assumes minimal ADUHELM revenue in 2022.
Shares of Biogen Inc. were down nearly 4% in pre-market trade on Thursday.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biogen Incmehr Nachrichten
16:04 |
NASDAQ Composite Index-Titel Biogen-Aktie: So viel Verlust hätte eine Biogen-Investition von vor 5 Jahren eingebracht (finanzen.at) | |
11.03.25 |
Freundlicher Handel: So performt der NASDAQ 100 am Nachmittag (finanzen.at) | |
11.03.25 |
Dienstagshandel in New York: NASDAQ 100 schwächer (finanzen.at) | |
10.03.25 |
Handel in New York: NASDAQ 100-Anleger nehmen Reißaus (finanzen.at) | |
10.03.25 |
NASDAQ 100 aktuell: NASDAQ 100-Anleger treten mittags Rückzug an (finanzen.at) | |
10.03.25 |
Anleger in New York halten sich zurück: NASDAQ Composite fällt am Mittag deutlich (finanzen.at) | |
10.03.25 |
NASDAQ Composite Index-Titel Biogen-Aktie: So viel Verlust hätte ein Biogen-Investment von vor 3 Jahren eingefahren (finanzen.at) | |
07.03.25 |
Pluszeichen in New York: NASDAQ 100 verbucht nachmittags Gewinne (finanzen.at) |
Analysen zu Biogen Incmehr Analysen
Aktien in diesem Artikel
Biogen Inc | 131,20 | 2,66% |
|